36.28
0.69 (1.94%)
| Previous Close | 35.59 |
| Open | 35.92 |
| Volume | 986,912 |
| Avg. Volume (3M) | 1,151,150 |
| Market Cap | 2,157,629,952 |
| Price / Sales | 30.13 |
| Price / Book | 0.840 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2026 |
| Profit Margin | 1,798.26% |
| Operating Margin (TTM) | -1,221.97% |
| Diluted EPS (TTM) | 11.54 |
| Quarterly Revenue Growth (YOY) | 6.60% |
| Total Debt/Equity (MRQ) | 3.61% |
| Current Ratio (MRQ) | 18.50 |
| Operating Cash Flow (TTM) | -401.46 M |
| Levered Free Cash Flow (TTM) | -237.66 M |
| Return on Assets (TTM) | -22.88% |
| Return on Equity (TTM) | 60.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Agios Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.65% |
| % Held by Institutions | 101.39% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CAPELLO JEFFREY D | - | - | 0 | 0 |
| OWEN ADAMS CATHERINE | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CAPELLO JEFFREY D | Director | 13 Jun 2026 | Option execute | 1,976 | - | - |
| OWEN ADAMS CATHERINE | Director | 13 Jun 2026 | Option execute | 1,976 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |